XTANT MEDICAL HOLDINGS, INC. Long-term Line of Credit, Noncurrent
XTANT MEDICAL HOLDINGS, INC. (XTNT) had Long-term Line of Credit, Noncurrent of $10.23 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation › Long-Term Debt, Excluding Current Maturities
us-gaap:LongTermLineOfCredit · last filed 2026-08-11
- 2026-06-30: Long-term Line of Credit, Noncurrent $10.23M.
- 2026-03-31: Long-term Line of Credit, Noncurrent $11.16M.
- 2025-12-31: Long-term Line of Credit, Noncurrent $14.00M.
- 2025-09-30: Long-term Line of Credit, Noncurrent $17.00M.
| Period end | Long-term Line of Credit, Noncurrent |
|---|---|
| 2026-06-30 | $10.23M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $11.16M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $14.00M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $17.00M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $22.00M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $22.00M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $22.00M 10-K · filed 2026-03-31 |
| 2024-09-30 | $22.00M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $22.00M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $17.00M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $17.00M 10-K · filed 2025-03-06 |
| 2023-09-30 | $17.00M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $17.00M 10-Q · filed 2023-08-01 |
| 2022-12-31 | $12.00M 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| NEPHROS INC (NEPH) | United States | $0.046B | 23.02 |
| SANUWAVE Health, Inc. (SNWV) | United States | $0.041B | 5.47 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| InspireMD, Inc. (NSPR) | $0.033B | ||
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| PAVmed Inc. (PAVM) | United States | $0.031B | -3.00 |